STOCK TITAN

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
partnership

Philips (NYSE: PHG) and Masimo (NASDAQ: MASI) have announced a renewed multi-year strategic partnership focused on advancing patient monitoring technologies. The collaboration will integrate Masimo's advanced monitoring technologies, including SET® pulse oximetry, Radius PPG, and sensor technology, into Philips' multi-parameter patient monitoring platforms.

The partnership aims to develop and co-promote next-generation monitoring solutions, with a focus on patient mobility, AI algorithms, and smart connected care. The integration will support clinicians with reliable data and actionable insights across bedside monitors, central stations, and wearable solutions within a unified system.

Loading...
Loading translation...

Positive

  • Integration of Masimo's advanced monitoring technologies into Philips' platforms enhances system capabilities
  • Partnership focuses on developing AI algorithms and next-generation monitoring solutions
  • Collaboration aims to reduce complexity and enhance interoperability in healthcare systems
  • Agreement supports expansion of smart, connected care solutions

Negative

  • None.

News Market Reaction 1 Alert

+1.24% News Effect

On the day this news was published, PHG gained 1.24%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

September 11, 2025

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Masimo (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-generation patient monitoring solutions. This expanded agreement reflects our commitment to empower clinicians with smarter, more integrated technologies that support better outcomes across the continuum of care.

Accelerating access to next-generation monitoring technologies 
At the heart of the expanded partnership is a joint effort to integrate Masimo’s advanced monitoring technologies – including SET® pulse oximetry, Radius PPG, and a range of sensor technology – into Philips’ multi-parameter patient monitoring platforms. This integration supports clinicians with reliable data and actionable insights across bedside monitors, central stations, and wearable solutions, while giving them the flexibility to use their preferred measurement technologies within a single, unified system. By embedding these capabilities into Philips’ monitoring ecosystem, the collaboration aims to reduce complexity, enhance interoperability, and deliver streamlined tools that support timely decision-making and continuity of care. 
 
Building on this foundation, Philips and Masimo also plan to collaborate on the development and co-promotion of next-generation monitoring solutions that reflect emerging clinical needs and evolving market demands such as the need for greater patient mobility. These efforts are focused on advancing smart, connected care and expanding access to innovative technologies, including AI algorithms, that have the potential to improve patient care over time. 
 
“Our priority is helping clinicians deliver the best possible care to their patients, and that means staying ahead of the curve,” said Julia Strandberg, Executive Vice President and Business Leader Connected Care at Royal Philips. “This partnership allows us to respond quickly to evolving clinical needs and market trends, integrating proven technologies into solutions that are easy to use, reliable, and scalable.”

“We are excited to continue to partner with Philips to bring Masimo’s newest innovations in wearables and artificial intelligence to Philips’ platforms,” said Katie Szyman, CEO of Masimo. “Expanding our strong, long-standing partnership with Philips allows us to build on our shared legacies of innovation and helps ensure that Masimo’s best-in-class technologies reach even more patients. Together, Masimo and Philips will continue to empower clinicians to transform patient care.”

A shared commitment to innovation and impact 
The renewed partnership underscores both companies’ dedication to transforming patient care through meaningful innovation. By bringing together Philips’ deep expertise in patient monitoring and Masimo’s advanced noninvasive technologies, the collaboration is focused on delivering integrated, clinically validated solutions that scale to meet the needs of healthcare providers. It also aligns with Philips’ broader strategy to work with industry-leading partners to enhance care delivery, improve operational efficiency, and support vendor-neutral interoperability across healthcare systems.

For further information, please contact:

Mark Groves
External Relations, Philips
Tel: +31 631 639 916
E-mail: mark.groves@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment


FAQ

What technologies will be integrated into Philips' monitoring platforms through the Masimo partnership?

The partnership will integrate Masimo's SET® pulse oximetry, Radius PPG, and sensor technology into Philips' multi-parameter patient monitoring platforms.

How will the Philips-Masimo partnership benefit healthcare providers?

The collaboration will reduce complexity, enhance interoperability, and deliver streamlined tools that support timely decision-making and continuity of care.

What are the main focus areas of the Philips-Masimo strategic collaboration?

The partnership focuses on developing AI algorithms, advancing smart connected care, expanding access to innovative technologies, and improving patient mobility solutions.

Who are the key executives involved in the Philips-Masimo partnership?

Julia Strandberg, Executive Vice President and Business Leader Connected Care at Philips, and Katie Szyman, CEO of Masimo, are the key executives leading the partnership.

What is the duration of the Philips-Masimo partnership agreement?

The agreement is described as a multi-year strategic collaboration, though specific duration details were not disclosed.
Koninklijke Phil

NYSE:PHG

PHG Rankings

PHG Latest News

PHG Latest SEC Filings

PHG Stock Data

25.35B
950.98M
5.42%
0.26%
Medical Devices
Healthcare
Link
Netherlands
Amsterdam